Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren in nmDMD
NCT03648827Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc. Primary endpoint: Percent Change From Baseline in Dystrophin Level at Week 40. Started Dec 2018; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03648827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03648827.